.png)
The FDA's accelerated approval of TUDRIQEV™ (vusolimogene oderparepvec), previously known as RP1, marks an important milestone for the melanoma community. Approved in combination with nivolumab for patients with unresectable advanced cutaneous melanoma whose disease has progressed after anti-PD-1 therapy, it offers a new treatment option for patients with limited alternatives.
As this promising oncolytic immunotherapy moved through clinical development, MRA has worked to provide the melanoma community with timely information - from explaining the science behind the therapy and the IGNYTE-3 clinical trial, to sharing expert perspectives and patient experiences.
Whether you're just learning about TUDRIQEV™ or want to better understand how this new treatment reached approval, we've gathered our most helpful resources below.
Our overview of the IGNYTE-3 clinical trial featured insights from Dr. Omid Hamid, co-director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute and a principal investigator of the IGNYTE-3 trial. He explained how RP1 works, who was eligible to participate in the IGNYTE-3 trial, and why researchers believe this engineered oncolytic virus represents an important advancement for patients whose melanoma has progressed after prior immunotherapy.
Before TUDRIQEV™ became an FDA approved therapy, patients like Jim Day helped make this milestone possible by participating in clinical trials.
Jim shares his experience enrolling in the IGNYTE study, how TUDRIQEV™ helped shrink tumors throughout his body, and why research gave him hope when he needed it most.
Read: Hope Through Research: Jim Day's RP1 Clinical Trial Experience
In this MRA Meet Up webinar, Dr. Yana Najjar of UPMC Hillman Cancer Center explained:
Watch: Oncolytic Immunotherapy, Clinical Trials, & the Emerging RP1 Treatment
Before TUDRIQEV™ became an approved treatment, many patients had questions about expanded access and compassionate use.
Our webinar with Dr. Eric Whitman of Atlantic Health System Cancer Care discussed how compassionate use works, when it may be considered, and how investigational therapies like RP1 fit into that process.
Watch: Compassionate Use in Melanoma & the Emerging RP1 Therapy
Our coverage of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the latest advances in melanoma research, including new data on TUDRIQEV™ (formerly RP1) and other next-generation oncolytic virus therapies.
We broke down new long-term data on TUDRIQEV™ from the IGNYTE trial, including encouraging three-year survival results that helped build the evidence supporting this therapy. We also explored promising findings on RP2, an oncolytic immunotherapy being investigated for both cutaneous and uveal melanoma, including a currently enrolling randomized phase II/III clinical trial in metastatic uveal melanoma (NCT06581406).
Read: Highlights in Melanoma Treatment Advances from ASCO 2026
The approval of TUDRIQEV™ represents years of scientific research, clinical investigation, and the willingness of patients to participate in clinical trials that make new treatments possible.
MRA was honored to work alongside peer organizations, including AIM at Melanoma and the Melanoma Research Foundation, to help amplify the melanoma community’s voice and advocate for continued progress in bringing new treatment options to patients.
We are grateful to the patients, caregivers, advocates, researchers, clinicians, and community members who helped move this therapy forward.
.png)
.png)
.png)
